Investigating how ASAP1 affects the spread of uveal melanoma
Official title: Targeting ASAP1-Controlled Signal Pathways to Inhibit Uveal Melanoma Metastasis
Funded at University of Nebraska Medical Center · NIH-10891549 · Data updated 2026-11-12
This study is looking at how a protein called ASAP1 affects the spread of uveal melanoma, a type of eye cancer, to find new ways to help prevent or treat it for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project start | March 16, 2018 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $280,904 |
| NIH project number | 5P20GM121316-07 |
| Project ID | NIH-10891549 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with uveal melanoma, particularly those showing signs of metastasis.
✕Less likely to help
Patients with non-melanoma eye cancers or those whose uveal melanoma is already at an advanced stage may not benefit from this research.
What this research studies
This research focuses on understanding the role of ASAP1 in the metastasis of uveal melanoma, a type of eye cancer. Researchers are exploring how ASAP1 influences cell behavior, including migration and invasion, which are critical for cancer spread. By studying these pathways, the project aims to identify potential therapeutic targets to prevent or treat metastatic disease in patients. The approach includes using laboratory models to observe the effects of manipulating ASAP1 levels on cancer cell behavior.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that inhibit the spread of uveal melanoma, improving patient outcomes.
How similar studies have gone: Previous research has shown that targeting similar pathways in other cancers has led to successful treatment strategies, suggesting potential for success in this area as well.
Where this research is happening
-
University of Nebraska Medical Center
Omaha, United States Active
Researchers
- Principal investigator: Yoo, Jae Hyuk — University of Nebraska Medical Center
- Study coordinator: Yoo, Jae Hyuk
Related research
Other NIH-funded projects on the same topics.
-
Understanding and targeting the genetic changes in uveal melanoma that lead to liver metastasis
This study is looking at how certain changes in genes and cells in uveal melanoma, a serious eye cancer, can lead to it spreading to the liver, and it hopes to find new treatments that could help high-risk patients manage this spread better.
-
Using small molecule drugs to improve CAR T cell therapy for Uveal Melanoma
This study is looking at a new way to make CAR T cell therapy work better for people with Uveal Melanoma, a rare eye cancer that can spread to the liver, by using special medicines to shrink tumors and boost the immune system's ability to fight them.
-
Targeting serotonin receptors to boost a cancer cell weakness in uveal melanoma
A small funding project tests whether blocking the serotonin HTR2B receptor can weaken mutant GNAQ/GNA11-driven uveal melanoma cells to help fight metastatic eye cancer.
-
Differing NAD+ kinase roles in melanoma spread
Researchers are studying how different NAD+ kinase forms affect the spread of melanoma, with the goal of finding new angles to prevent metastasis.
-
Understanding how palmitoylation affects Cadherin-Catenin cell adhesion and lung melanoma spread
This NIH grant studies how a chemical modification called palmitoylation influences how melanoma cells stick together and spread to the lungs, with potential to improve future treatments.
-
Dual mRNA therapeutics aimed at liver metastasis from uveal melanoma
A new approach uses two mRNA-based therapies designed to target liver metastases in adults with uveal melanoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.